Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
e-Letters: Comments and Responses

Response to Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616

  1. Xilin Zhou and
  2. Ping Zhang⇑
  1. Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA
  1. Corresponding author: Ping Zhang, paz2{at}cdc.gov
Diabetes Care 2020 Dec; 43(12): e206-e207. https://doi.org/10.2337/dci20-0063
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

We thank Sathish et al. (1) for their interest in our systematic review on the cost-effectiveness of interventions to prevent type 2 diabetes (T2D) among high-risk individuals and whole populations (2). Sathish et al. provided additional evidence from India and Bangladesh on the cost-effectiveness of T2D prevention interventions for low- and middle-income countries (LMICs). These new studies, along with one earlier study from India (3) and two studies from China (4,5), provide direct evidence from LMICs that in-person lifestyle interventions are indeed cost-effective.

The cost-effectiveness results presented in studies cited by Sathish et al. would be more favorable if the long-term benefits of the lifestyle interventions were considered. Health benefits of lifestyle interventions aimed at preventing T2D can last beyond the intervention period. Thirty years’ follow-up of the Da Qing Diabetes Prevention Outcome Study showed that a 6-year lifestyle intervention program among persons with impaired glucose tolerance (IGT) could delay the onset of T2D for up to 24 years after the active intervention period (6). Lifestyle interventions among persons with IGT can also reduce cardiovascular disease, severe retinopathy, and deaths due to cardiovascular disease and from all causes (6). Simulation studies that included long-term health and economic consequences of the lifestyle interventions from high-income countries showed that the interventions were more cost-effective than studies that used data from trials alone (2). For LMICs, studies in China found that, if evaluated over 40 years or the lifetime, the diet and exercise interventions could even be cost-saving (4,5).

Besides interventions targeting high-risk individuals, there are also newly published studies for the cost-effectiveness of interventions on T2D prevention targeting whole populations in LMICs. For example, a recent study in Mexico found that an excise tax of one or two pesos per liter on sugar-sweetened beverages was cost-saving for a period of 10 years from the health care system perspective (7). Studies in the Philippines and South Africa also found the sugar-sweetened beverage tax to be cost-saving in preventing T2D (8,9).

Despite the new evidence, there is still a critical research gap of economic evaluations on T2D prevention interventions for LMICs. LMICs lack country-specific data on costs and effectiveness. Even for studies conducted in LMICs, the results may still not be transferable to other LMICs as the costs and effectiveness of the interventions may differ. Therefore, more rigorous economic evaluations of T2D prevention interventions in various LMICs and worldwide would be beneficial to guide resource allocations for curbing the diabetes pandemic.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • The findings and conclusions are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

  • © 2020 by the American Diabetes Association
https://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Sathish T,
    2. Shaw JE,
    3. Oldenburg B,
    4. Mahal A
    . Comment on Zhou et al. Cost-effectiveness of diabetes prevention interventions targeting high-risk individuals and whole populations: a systematic review. Diabetes Care 2020;43:1593–1616 (Letter). Diabetes Care 2020;43:e204–e205.DOI: 10.2337/dc20-2124
    OpenUrlFREE Full Text
  2. ↵
    1. Zhou X,
    2. Siegel KR,
    3. Ng BP, et al
    . Cost-effectiveness of diabetes prevention interventions targeting high-risk individuals and whole populations: a systematic review. Diabetes Care 2020;43:1593–1616
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Ramachandran A,
    2. Snehalatha C,
    3. Yamuna A,
    4. Mary S,
    5. Ping Z
    . Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007;30:2548–2552
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Liu X,
    2. Li C,
    3. Gong H, et al
    . An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. BMC Public Health 2013;13:729
    OpenUrlPubMed
  5. ↵
    1. Ma J,
    2. Wan X,
    3. Wu B
    . The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting. J Diabetes Res 2020;2020:7410797
    OpenUrl
  6. ↵
    1. Gong Q,
    2. Zhang P,
    3. Wang J, et al.; Da Qing Diabetes Prevention Study Group
    . Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol 2019;7:452–461
    OpenUrlPubMed
  7. ↵
    1. Basto-Abreu A,
    2. Barrientos-Gutiérrez T,
    3. Vidaña-Pérez D, et al
    . Cost-effectiveness of the sugar-sweetened beverage excise tax in Mexico. Health Aff (Millwood) 2019;38:1824–1831
    OpenUrl
  8. ↵
    1. Saxena A,
    2. Koon AD,
    3. Lagrada-Rombaua L,
    4. Angeles-Agdeppa I,
    5. Johns B,
    6. Capanzana M
    . Modelling the impact of a tax on sweetened beverages in the Philippines: an extended cost-effectiveness analysis. Bull World Health Organ 2019;97:97–107
    OpenUrl
  9. ↵
    1. Saxena A,
    2. Stacey N,
    3. Puech PDR,
    4. Mudara C,
    5. Hofman K,
    6. Verguet S
    . The distributional impact of taxing sugar-sweetened beverages: findings from an extended cost-effectiveness analysis in South Africa. BMJ Glob Health 2019;4:e001317
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes Care: 43 (12)

In this Issue

December 2020, 43(12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Response to Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Response to Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616
Xilin Zhou, Ping Zhang
Diabetes Care Dec 2020, 43 (12) e206-e207; DOI: 10.2337/dci20-0063

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Response to Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616
Xilin Zhou, Ping Zhang
Diabetes Care Dec 2020, 43 (12) e206-e207; DOI: 10.2337/dci20-0063
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
  • Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
  • Comment on Zhou et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care 2020;43:1593–1616
Show more e-Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.